Author/Authors :
Zekavat، Omid Reza نويسنده Hematology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran; , , Makarem، Ali Reza نويسنده Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran; , , Haghpanah، Sezaneh نويسنده , , Karamizadeh، Zohreh نويسنده Department of Pediatric Endocrinology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran , , Javad، Parvin نويسنده Hematology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran; , , KARIMI، MEHRAN نويسنده ,
Abstract :
Hydroxyurea (HU) has been successfully used in patients with B-thalassemia intermedia (B-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with B-TI. Seventy-five patients with B-TI aged?11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with B-TI without HU were considered as a control group. Serum levels of thyroid stimulating hormone (TSH) and T4 were measured. The mean age of the participants was 22.7±5.1 years (age range=12-41 years). Serum ferritin level had no significant correlation with HU consumption (P > 0.05). Overall, we detected 10 (9.4%) patients with hypothyroidism. We found that the use of HU at a dose of 8-15 mg/kg/day has no significant association with thyroid function in B-TI patients. However, due to the small sample size in our study, documentation of this finding needs further studies with higher numbers of patients.
